AAAAAA
Results: 1-25/32
Authors:
Wahlby, U
Jonsson, EN
Karlsson, MO
Citation: U. Wahlby et al., Assessment of actual significance levels for covariate effects in NONMEM, J PHARMA PH, 28(3), 2001, pp. 231-252
Authors:
Hassan, SB
de la Torre, M
Nygren, P
Karlsson, MO
Larsson, R
Jonsson, E
Citation: Sb. Hassan et al., A hollow fiber model for in vitro studies of cytotoxic compounds: activityof the cyanoguanidine CHS 828, ANTI-CANC D, 12(1), 2001, pp. 33-42
Authors:
Abelo, A
Gabrielsson, J
Holstein, B
Eriksson, UG
Holmberg, J
Karlsson, MO
Citation: A. Abelo et al., Pharmacodynamic modelling of reversible gastric acid pump inhibition in dog and man, EUR J PH SC, 14(4), 2001, pp. 339-346
Authors:
Aarons, L
Karlsson, MO
Mentre, F
Rombout, F
Steimer, JL
van Peer, A
Citation: L. Aarons et al., Role of modelling and simulation in Phase I drug development, EUR J PH SC, 13(2), 2001, pp. 115-122
Authors:
Henningsson, A
Karlsson, MO
Vigano, L
Gianni, L
Verweij, J
Sparreboom, A
Citation: A. Henningsson et al., Mechanism-based pharmacokinetic model for paclitaxel, J CL ONCOL, 19(20), 2001, pp. 4065-4073
Authors:
van Zuylen, L
Karlsson, MO
Verweij, J
Brouwer, E
de Bruijn, P
Nooter, K
Stoter, G
Sparreboom, A
Citation: L. Van Zuylen et al., Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles, CANC CHEMOT, 47(4), 2001, pp. 309-318
Authors:
Grahnen, A
Karlsson, MO
Citation: A. Grahnen et Mo. Karlsson, Concentration-controlled or effect-controlled trials - Useful alternativesto conventional dose-controlled trials?, CLIN PHARMA, 40(5), 2001, pp. 317-325
Authors:
Brynne, L
McNay, JL
Schaefer, HG
Swedberg, K
Wiltse, CG
Karlsson, MO
Citation: L. Brynne et al., Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure, BR J CL PH, 51(1), 2001, pp. 35-43
Authors:
Cullberg, M
Eriksson, UG
Larsson, M
Karlsson, MO
Citation: M. Cullberg et al., Population modelling of the effect of inogatran, at thrombin inhibitor, onex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease, BR J CL PH, 51(1), 2001, pp. 71-79
Authors:
Jonsson, E
Friberg, LE
Karlsson, MO
Hassan, SB
Nygren, P
Kristensen, J
Tholander, B
Binderup, L
Larsson, R
Citation: E. Jonsson et al., In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients, CANCER LETT, 162(2), 2001, pp. 193-200
Authors:
Sandstrom, M
Karlsson, MO
Ljungman, P
Hassan, Z
Jonsson, EN
Nilsson, C
Ringden, O
Oberg, G
Bekassy, A
Hassan, M
Citation: M. Sandstrom et al., Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients, BONE MAR TR, 28(7), 2001, pp. 657-664
Authors:
Hassan, SB
Jonsson, E
Larsson, R
Karlsson, MO
Citation: Sb. Hassan et al., Model for time dependency of cytotoxic effect of CHS 828 in vitro suggeststwo different mechanisms of action, J PHARM EXP, 299(3), 2001, pp. 1140-1147
Authors:
Jonsson, E
Friberg, LE
Karlsson, MO
Hassan, SB
Freijs, A
Hansen, K
Larsson, R
Citation: E. Jonsson et al., Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats, CANC CHEMOT, 46(6), 2000, pp. 493-500
Authors:
Simonsen, LE
Wahlby, U
Sandstrom, M
Freijs, A
Karlsson, MO
Citation: Le. Simonsen et al., Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats, ANTICANC R, 20(3A), 2000, pp. 1519-1525
Authors:
Friberg, LE
Brindley, CJ
Karlsson, MO
Devlin, AJ
Citation: Le. Friberg et al., Models of schedule dependent haematological toxicity of 2 '-deoxy-2 '-methylidenecytidine (DMDC), EUR J CL PH, 56(8), 2000, pp. 567-574
Authors:
Abelo, A
Eriksson, UG
Karlsson, MO
Larsson, H
Gabrielsson, J
Citation: A. Abelo et al., A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog, J PHARM EXP, 295(2), 2000, pp. 662-669
Authors:
Friberg, LE
Freijs, A
Sandstrom, M
Karlsson, MO
Citation: Le. Friberg et al., Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats, J PHARM EXP, 295(2), 2000, pp. 734-740
Authors:
Brynne, L
Paalzow, LK
Karlsson, MO
Citation: L. Brynne et al., Consequence of exercise on the cardiovascular effects of I-propranolol in spontaneously hypertensive rats, J PHARM EXP, 294(3), 2000, pp. 1201-1208
Authors:
Karlsson, MO
Schoemaker, RC
Kemp, B
Cohen, AF
van Gerven, JMA
Tuk, B
Peck, CC
Danhof, M
Citation: Mo. Karlsson et al., A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep, CLIN PHARM, 68(2), 2000, pp. 175-188
Authors:
Gisleskog, PO
Hermann, D
Hammarlund-Udenaes, M
Karlsson, MO
Citation: Po. Gisleskog et al., Validation of a population pharmacokinetic/ pharmacodynamic model for 5 alpha-reductase inhibitors, EUR J PH SC, 8(4), 1999, pp. 291-299
Likelihood-based diagnostics for influential individuals in non-linear mixed effects model selection
Authors:
Sadray, S
Jonsson, EN
Karlsson, MO
Citation: S. Sadray et al., Likelihood-based diagnostics for influential individuals in non-linear mixed effects model selection, PHARM RES, 16(8), 1999, pp. 1260-1265
Authors:
Sandstrom, M
Simonsen, LE
Freijs, A
Karlsson, MO
Citation: M. Sandstrom et al., The pharmacokinetics of epirubicin and docetaxel in combination in rats, CANC CHEMOT, 44(6), 1999, pp. 469-474
Authors:
Gardmark, M
Brynne, L
Hammarlund-Udenaes, M
Karlsson, MO
Citation: M. Gardmark et al., Interchangeability and predictive performance of empirical tolerance models (vol 36, pg 145, 1999), CLIN PHARMA, 36(5), 1999, pp. 328-328
Authors:
Gardmark, M
Brynne, L
Hammarlund-Udenaes, M
Karlsson, MO
Citation: M. Gardmark et al., Interchangeability and predictive performance of empirical tolerance models, CLIN PHARMA, 36(2), 1999, pp. 145-167
Authors:
Hassan, M
Svensson, USH
Ljungman, P
Bjorkstrand, B
Olsson, H
Bielenstein, M
Abdel-Rehim, M
Nilsson, C
Johansson, M
Karlsson, MO
Citation: M. Hassan et al., A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients, BR J CL PH, 48(5), 1999, pp. 669-677